Pancreatic ductal adenocarcinoma is projected to become the second-leading cause of cancer death in the United States by 2030 ...

The investigational combination of bezuclastinib (CGT9486) and sunitinib (Sutent) yielded clinically meaningful benefits with favorable tolerability in patients with gastrointestinal stromal tumors ...

A gastroenterologist at the Mayo Clinic who treats patients with pancreatic cancer shares the warning signs he looks for in ...

The biotech reported positive trial data for a treatment targeting patients with gastrointestinal stromal tumors.

Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors November 8:00 ...

Cogent Biosciences (NASDAQ: COGT) shares skyrocketed over 120% after the biotech company announced groundbreaking results ...

Use of teduglutide appeared safe for patients with short bowel syndrome, with no increased incidence of gastrointestinal ...

Liver cells are indispensable for research—for drug testing, to better understand diseases such as hepatitis, fatty liver, cirrhosis, or liver cancer and for development of future cell therapies.

Using targeted radiation during surgery—referred to as intraoperative radiation—to eliminate pancreatic cancer cells that ...

DelveInsight's, “Gastrointestinal Stromal Tumors Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline ...